Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study
American Journal of Clinical Dermatology · 2024
DOI: 10.1007/s40257-024-00873-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Clinical Dermatology, 2024. Verfasst von Yu Lan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-Sen University, 3025 Shennan Road Central, Shenzhen, 518033, China. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Dermatitis, Exfoliative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: Shenzhen Innovation and Technology Commission Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-Sen University, 3025 Shennan Road Central, Shenzhen, 518033, China.
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Haiyuan 1st Road, Shenzhen, 518040, China.
- Department of Dermatology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, 25 Yu'an 2nd Road, 30 District, Baoan District, Shenzhen, 518133, China.
- Department of Dermatology, Shenzhen Bao'an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, 25 Yu'an 2nd Road, 30 District, Baoan District, Shenzhen, 518133, China. oldduan2000@163.com.
- Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-Sen University, 3025 Shennan Road Central, Shenzhen, 518033, China. zhangzy@hku-szh.org.
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Haiyuan 1st Road, Shenzhen, 518040, China. zhangzy@hku-szh.org.
Förderung
- Shenzhen Innovation and Technology Commission Foundation
Zitieren
APA
Lan, Y., Wu, X., Ni, L., Liu, Y., Yan, T., Duan, D., & Zhang, Z. (2024). Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00873-0
Vancouver
Lan Y, Wu X, Ni L, Liu Y, Yan T, Duan D, et al. Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study. American Journal of Clinical Dermatology. 2024. doi:10.1007/s40257-024-00873-0
BibTeX
@article{Lan2024,
author = {Lan, Yu and Wu, Xiaoyan and Ni, Linya and Liu, Yuhua and Yan, Tianmeng and Duan, Dejian and Zhang, Zhenying},
title = {Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study},
journal = {American Journal of Clinical Dermatology},
year = {2024},
doi = {10.1007/s40257-024-00873-0}
}
EUVIMED